Revelation Biosciences Inc (REVB)

$2.71 +0.13 (5.04%)
Market Cap 4.39M
Revenue (ttm) 0.00
Net Income (ttm) -15.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 96,000
Avg Vol 205,218
Day's Range N/A - N/A
Shares Out 1.70M
Stochastic %K 73%
Beta -0.06
Analysts Strong Sell
Price Target $40.73

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed...

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 800-3717
Address:
4660 La Jolla Village Drive, Suite 100, San Diego, United States
CryptoSenderX
CryptoSenderX Aug. 19 at 11:03 AM
$VKTX & $REVB charts saying we’re ready to take off
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 19 at 4:43 AM
$REVB good start
0 · Reply
CryptoSenderX
CryptoSenderX Aug. 18 at 6:26 PM
$PPCB what a day for the bulls 🪐 $REVB here you are the next sleeping giant 💥
1 · Reply
CryptoSenderX
CryptoSenderX Aug. 18 at 6:17 PM
$REVB 🪐 undervalued and reiterated strong buy with 60$ price target Risk Reward Play is absolutely insane Potential Short Squeezer with huge gap up
1 · Reply
makedatbread88
makedatbread88 Aug. 18 at 2:31 PM
$REVB Major buy alert!!! 677k float, recent reverse split, has Q3 catalyst for data. Recent $21 price target given. This one could go nuts 1 week chart showing clear accumulation going on too 🚀🐎
1 · Reply
Prof_Amen1
Prof_Amen1 Aug. 18 at 1:08 PM
$REVB 6$ coming
0 · Reply
SkyLonger
SkyLonger Aug. 18 at 11:41 AM
$REVB super ....
0 · Reply
WealthExchange
WealthExchange Aug. 17 at 11:55 PM
$REVB: Low float biotech with a major catalyst readout in the near term (picture below). I’m looking to accumulate a position between 2.4-2.65 looking for 3, 3.5, 5, and 5.8 if they end up releasing positive data. 4m market cap 1.7m float. Bad data could drop the stock 30-50%.
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 15 at 9:52 PM
$REVB next week is crucial
0 · Reply
SkyLonger
SkyLonger Aug. 14 at 1:06 PM
$REVB float is low under 2M
0 · Reply
Latest News on REVB
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Aug 8, 2025, 6:30 AM EDT - 11 days ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Jul 24, 2025, 9:00 AM EDT - 25 days ago

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Jul 16, 2025, 9:00 AM EDT - 4 weeks ago

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Jul 1, 2025, 5:26 PM EDT - 6 weeks ago

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025, 4:05 PM EDT - 2 months ago

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025, 8:00 AM EDT - 2 months ago

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025, 4:05 PM EDT - 3 months ago

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

May 8, 2025, 4:15 PM EDT - 3 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Apr 29, 2025, 9:00 AM EDT - 3 months ago

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Mar 17, 2025, 6:00 AM EDT - 5 months ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Mar 13, 2025, 6:00 AM EDT - 5 months ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Mar 6, 2025, 4:15 PM EST - 5 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Feb 26, 2025, 6:00 AM EST - 6 months ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Feb 24, 2025, 6:00 AM EST - 6 months ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Jan 24, 2025, 6:00 AM EST - 7 months ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Jan 21, 2025, 6:00 AM EST - 7 months ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Jan 13, 2025, 6:00 AM EST - 7 months ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Jan 6, 2025, 6:00 AM EST - 8 months ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 3, 2024, 8:38 AM EST - 9 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Dec 2, 2024, 6:00 AM EST - 9 months ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Nov 12, 2024, 6:00 AM EST - 10 months ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Nov 8, 2024, 4:15 PM EST - 10 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Sep 24, 2024, 6:00 AM EDT - 11 months ago

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Aug 21, 2024, 5:30 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Jun 13, 2024, 9:21 AM EDT - 1 year ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

May 10, 2024, 4:52 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Mar 22, 2024, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Mar 13, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Mar 12, 2024, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Mar 4, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Feb 13, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Top 5 Health Care Stocks That Are Preparing To Pump In February

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

CNSP GILD ZLAB

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Feb 5, 2024, 4:41 PM EST - 1 year ago

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Feb 1, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Jan 30, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Jan 23, 2024, 9:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

Nov 13, 2023, 4:05 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

Oct 12, 2023, 9:00 AM EDT - 2 years ago

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Oct 4, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Oct 2, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

Aug 11, 2023, 4:10 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Jun 29, 2023, 9:00 AM EDT - 2 years ago

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

Jun 12, 2023, 4:15 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

May 22, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Mar 30, 2023, 5:42 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Mar 13, 2023, 9:00 AM EDT - 2 years ago

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 6, 2023, 9:00 AM EST - 2 years ago

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

Feb 13, 2023, 4:20 PM EST - 2 years ago

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

CryptoSenderX
CryptoSenderX Aug. 19 at 11:03 AM
$VKTX & $REVB charts saying we’re ready to take off
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 19 at 4:43 AM
$REVB good start
0 · Reply
CryptoSenderX
CryptoSenderX Aug. 18 at 6:26 PM
$PPCB what a day for the bulls 🪐 $REVB here you are the next sleeping giant 💥
1 · Reply
CryptoSenderX
CryptoSenderX Aug. 18 at 6:17 PM
$REVB 🪐 undervalued and reiterated strong buy with 60$ price target Risk Reward Play is absolutely insane Potential Short Squeezer with huge gap up
1 · Reply
makedatbread88
makedatbread88 Aug. 18 at 2:31 PM
$REVB Major buy alert!!! 677k float, recent reverse split, has Q3 catalyst for data. Recent $21 price target given. This one could go nuts 1 week chart showing clear accumulation going on too 🚀🐎
1 · Reply
Prof_Amen1
Prof_Amen1 Aug. 18 at 1:08 PM
$REVB 6$ coming
0 · Reply
SkyLonger
SkyLonger Aug. 18 at 11:41 AM
$REVB super ....
0 · Reply
WealthExchange
WealthExchange Aug. 17 at 11:55 PM
$REVB: Low float biotech with a major catalyst readout in the near term (picture below). I’m looking to accumulate a position between 2.4-2.65 looking for 3, 3.5, 5, and 5.8 if they end up releasing positive data. 4m market cap 1.7m float. Bad data could drop the stock 30-50%.
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 15 at 9:52 PM
$REVB next week is crucial
0 · Reply
SkyLonger
SkyLonger Aug. 14 at 1:06 PM
$REVB float is low under 2M
0 · Reply
AllandaleCapital
AllandaleCapital Aug. 13 at 8:32 PM
$REVB Market Cap: $4.3M Enterprise Value: $0.3M Float / OS: 1.70M / 1.70M 👀 Institutional Ownership: 0.2% Live Short Interest: 14.06% Warrants May 2025 Class H – 4.85M @ $2.25, Roth, full ratchet/reset, exp. May 29, 2030 Dec 2024 Class G – 1.85M @ $3.30, Armistice/Hudson Bay/Sabby, reset/proportional/full ratchet, exp. Dec 3, 2029 Aug 2024 Inducement – 21,502 @ $3.30, Armistice/Hudson Bay/Sabby, undisclosed protection, exp. Aug 22, 2029 Dec 2024 Class F – 20,833 @ $0.00, Armistice/Hudson Bay/Sabby, alternate cashless, exp. Dec 3, 2026 Feb 2024 – 1,686 @ $48.00, Armistice/Hudson Bay/Sabby, full ratchet/reset, exp. Feb 1, 2029 SPAC – 216 @ $579,600.00, undisclosed protection, exp. Jan 9, 2027 Jul 2022 – 165 @ $30,240.00, Roth, undisclosed protection, exp. Jul 28, 2027 Feb 2023 – 161 @ $0.00, Sabby, full ratchet/alternate cashless, exp. Feb 13, 2028 Jan 2022 PIPE – 51 @ $165,816.00, Armistice, customary anti-dilution, exp. Jan 24, 2027 Shelf Jul 2024 Shelf – $1.75M raisable, $50M total cap, baby shelf restricted, exp. Jul 26, 2027
0 · Reply
SkyLonger
SkyLonger Aug. 13 at 2:40 PM
$REVB
0 · Reply
hassan101
hassan101 Aug. 12 at 6:37 PM
$REVB 👌
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Aug. 12 at 5:03 PM
💊 New Signal: $REVB 📥 Entry: $2.4800 💥 Suggested One-Shot: $3.0400 (Suggested – Optional) #stocksignals #REVB
0 · Reply
OrangeJoolius
OrangeJoolius Aug. 11 at 5:46 PM
$REVB This is toast, shame on management.
0 · Reply
SkyLonger
SkyLonger Aug. 11 at 12:00 PM
$REVB get your 🐤🐤🐤🐤🐤🐤
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 10 at 9:06 AM
$REVB we need to get back above 2.73 tomorrow
0 · Reply
Prof_Amen1
Prof_Amen1 Aug. 10 at 9:03 AM
$REVB we need to get back above 2.73 tomorrow
0 · Reply
HyperBulls
HyperBulls Aug. 8 at 8:01 PM
$REVB Loaded up more bullets, this is ready to fly within this or next month, it will take off.
0 · Reply
Baraa_MD
Baraa_MD Aug. 8 at 4:24 PM
$REVB https://scr.zacks.com/research-reports/companies-by-name/default.aspx#:~:text=REVB%3A%20Gemini%20Results%20to%20be%20Released%20Soon $21.45 price valuation
0 · Reply
ZacksSCR
ZacksSCR Aug. 8 at 4:11 PM
$REVB To Release Test Results This Quarter https://buff.ly/HeUwqFF
0 · Reply
d_risk
d_risk Aug. 8 at 2:54 PM
$REVB - REVELATION BIOSCIENCES, INC. - 10Q - Updated Risk Factors REVB flags AI’s growing impact on biotech as a new risk; all other risk factors, including FDA workforce and regulatory delays, remain unchanged. #Biotechnology #MarketImpact #FDADelays #RegulatoryRisk #ArtificialIntelligence 🟢 Added 🟠 Removed https://d-risk.ai/REVB/10-Q/2025-08-07
0 · Reply